PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today posted to the company website an overview of new, phase II data on the combination therapy of two small molecule antivirals in development for the treatment of chronic hepatitis C -- BMS-790052, an NS5A inhibitor, and BMS-650032, an NS3 protease inhibitor -- alone or with pegylated interferon and ribavirin. The data were presented today at the 61st Annual Meeting of the American Association for the Study of the Liver Diseases in Boston.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.
Bristol-Myers SquibbMedia:Cristi Barnett, 609-252-6028cristi.barnett@bms.comorInvestors:John Elicker, 609-252-4611john.elicker@bms.com